Relmada Therapeutics (RLMD) Return on Equity (ROE) (2013 - 2026)
Relmada Therapeutics (RLMD) Return on Equity (ROE) from May 31, 2013 to Mar 31, 2026. The TTM Relmada Therapeutics (RLMD) Return on Equity (ROE) is -8.71%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual ROE
Quarterly ROE
Annual Return on Equity (ROE) change of Relmada Therapeutics (RLMD)
| Year | Return on Equity (ROE) | Change |
|---|---|---|
| 2025 | -66.34% | -70.54% |
| 2024 | -225.17% | +94.56% |
| 2023 | -115.73% | +3.50% |
| 2022 | -111.82% | +85.19% |
| 2021 | -60.38% | +7.22% |
| 2020 | -56.32% | +334.03% |
| 2019 | -12.98% | -94.30% |
| 2019 | -227.60% | N/A |
| 2019 | -227.60% | -239.96% |
| 2018 | 162.61% | N/A |
| 2018 | 162.61% | -137.74% |
| 2017 | -430.82% | +921.21% |
| 2016 | -42.19% | -82.13% |
| 2015 | -236.10% | -313.28% |
| 2013 | 110.70% | N/A |
| 2011 | 0.00% | N/A |